Transcend Capital Advisors LLC Purchases 1,273 Shares of Danaher Corporation $DHR

Transcend Capital Advisors LLC grew its position in Danaher Corporation (NYSE:DHR) by 9.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,203 shares of the conglomerate’s stock after purchasing an additional 1,273 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Danaher were worth $2,806,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Hills Bank & Trust Co grew its stake in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock worth $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC grew its stake in shares of Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after acquiring an additional 53 shares during the last quarter. Sageworth Trust Co grew its stake in shares of Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock worth $493,000 after acquiring an additional 54 shares during the last quarter. 1834 Investment Advisors Co. grew its stake in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 54 shares during the last quarter. Finally, Bruce G. Allen Investments LLC grew its stake in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after acquiring an additional 54 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.20% of the company’s stock.

Danaher Stock Up 0.1%

DHR opened at $223.03 on Monday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm’s fifty day moving average price is $202.73 and its two-hundred day moving average price is $198.57. The company has a market capitalization of $157.54 billion, a P/E ratio of 45.99, a P/E/G ratio of 3.41 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the company earned $1.71 earnings per share. The business’s revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is currently 26.39%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Bank of America lowered their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Barclays raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. JPMorgan Chase & Co. raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Cowen restated a “buy” rating on shares of Danaher in a research note on Wednesday. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.